

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**RemeGen Co., Ltd.\***

**榮昌生物製藥(煙台)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 9995)**

**THE FIRST GRANT OF THE RESTRICTED SHARES  
UNDER THE 2022 A SHARE INCENTIVE SCHEME**

The Board is pleased to announce that the conditions for the First Grant are satisfied and it is determined that 2,869,450 Restricted Shares were granted to 188 Incentive Participants on December 28, 2022, at a price of RMB36.36 per A Share.

Reference is made to the following announcements and circular of RemeGen Co., Ltd.\* (榮昌生物製藥(煙台)股份有限公司) (the “**Company**”): (i) the announcement dated October 16, 2022, in relation to, among other things, the proposed adoption of the 2022 A Share Incentive Scheme (the “**Scheme**”); (ii) the circular of the EGM and the Class Meetings dated December 12, 2022, in relation to, among other things, the proposed adoption of the Scheme; and (iii) the poll results announcement dated December 28, 2022, in relation to, among other things, the approval on the proposed adoption of the Scheme at the EGM and the Class Meetings. Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the above announcements and the circular.

The Board is pleased to announce that the conditions for the First Grant are satisfied and it is determined that 2,869,450 Restricted Shares were granted to 188 Incentive Participants on December 28, 2022, at a price of RMB36.36 per A Share.

## **I. SATISFACTION OF CONDITIONS OF THE FIRST GRANT**

According to the Scheme, the Company shall grant Restricted Shares to the Participants under the First Grant and make an announcement within 60 days after the Scheme is considered and approved at the EGM and the Class Meetings. It is determined by the Board that the conditions of the First Grant are satisfied according to the relevant laws and regulations and provisions under the Scheme.

## **II. PARTICULARS OF THE FIRST GRANT**

1. Grant Date: December 28, 2022;
2. Number of Restricted Shares granted: 2,869,450 A Shares;
3. Number of Incentive Participants granted: 188 individuals;
4. Grant Price: RMB36.36 per A Share;

Market Price: The closing price of the A Shares of the Company on December 28, 2022 is RMB75.05 per A Share;

5. Source of Restricted Shares: A Shares issued by the Company under the Specific Mandate granted at the EGM and Class Meetings;
6. Validity Period and Attribution arrangements:

The Validity Period of the Scheme shall commence on the date of the First Grant and end on the date on which all Restricted Shares granted to the Incentive Participants have been attributed or lapsed.

- (I) The Restricted Shares granted under the Incentive Scheme may be attributed in tranches as per the agreed proportions upon the Incentive Participants satisfying the corresponding Attribution Conditions. The Attribution Date must be a trading day, and the period during which Attribution is not permitted under the listing rules of the stock exchanges is not included.

The Restricted Shares granted under the Incentive Participants shall not be attributed in the following periods:

1. Within sixty days and thirty days prior to the announcement of the annual reports and of the semi-annual reports, respectively, and on the date of the announcement for the Company, or in the event of postponement in publishing the periodic reports for special reasons, thirty days prior to the original announcement date and ending on one day prior to the announcement date;

2. Ten days prior to the release of the Company's quarterly reports, results forecast or preliminary report;
3. From the date of a major event which may have a material impact on the trading price of the Company's securities and derivatives or during the process of decision making until the date of legal disclosure of the same;
4. Other periods stipulated by stock exchanges.

If the relevant regulations of the stock exchanges regarding the Attribution Period change during the Validity Period of the Incentive Scheme, the Attribution Date shall comply with the relevant laws, regulations and regulatory documents after the amendment.

(II) The Restricted Shares to be granted under the Incentive Scheme have different Attribution arrangements for Class A and Class B interests respectively.

1. The Restricted Shares of Class A interests shall be attributed in five tranches after 12 months from the Grant Date. The specific Attribution arrangement is as follows:

<b>Class A interests</b>		<b>Percentage of the number of attributive interests to the total number of granted interests</b>
<b>Attribution arrangement</b>	<b>Time of Attribution</b>	
First Attribution Period	From the first trading day after the expiry of 12 months following the date of the corresponding interest until the last trading day within the 24 months following the Grant Date for corresponding interest	20%
Second Attribution Period	From the first trading day after the expiry of 24 months following the date of the corresponding interest until the last trading day within the 36 months following the Grant Date for corresponding interest	20%

## Class A interests

<b>Attribution arrangement</b>	<b>Time of Attribution</b>	<b>Percentage of the number of attributive interests to the total number of granted interests</b>
Third Attribution Period	From the first trading day after the expiry of 36 months following the date of the corresponding interest until the last trading day within the 48 months following the Grant Date for corresponding interest	20%
Fourth Attribution Period	From the first trading day after the expiry of 48 months following the date of the corresponding interest until the last trading day within the 60 months following the Grant Date for corresponding interest	20%
Fifth Attribution Period	From the first trading day after the expiry of 60 months following the date of the corresponding interest until the last trading day within the 72 months following the Grant Date for corresponding interest	20%

2. The Restricted Shares under Class B interests shall be attributed in four tranches after 24 months from the Grant Date. The specific Attribution arrangement is as follows:

<b>Class B interests</b>		<b>Percentage of the number of attributive interests to the total number of granted interests</b>
<b>Attribution arrangement</b>	<b>Time of Attribution</b>	
First Attribution Period	From the first trading day after the expiry of 24 months following the date of the corresponding interest until the last trading day within the 36 months following the Grant Date for corresponding interest	20%
Second Attribution Period	From the first trading day after the expiry of 36 months following the date of the corresponding interest until the last trading day within the 48 months following the Grant Date for corresponding interest	40%
Third Attribution Period	From the first trading day after the expiry of 48 months following the date of the corresponding interest until the last trading day within the 60 months following the Grant Date for corresponding interest	20%
Fourth Attribution Period	From the first trading day after the expiry of 60 months following the date of the corresponding interest until the last trading day within the 72 months following the Grant Date for corresponding interest	20%

Restricted Shares that do not attribute within the above-mentioned agreed period or that cannot be applied for attribution for that period due to failure to meet the Attribution Conditions shall not be attributed and shall lapse.

Prior to the Attribution, the Restricted Shares granted to the Incentive Participants under the Incentive Scheme shall not be transferred or used to guarantee or repay debts. For the Restricted Shares granted to the Incentive Participants but not yet attributed, shares increased due to capitalisation issue, bonus issue, etc. are also subject to the Attribution Conditions, and shall not be transferred or used to guarantee or repay debts. Where the Restricted Shares are not allowed to be attributed at that time, shares obtained for the aforementioned reasons shall also not be attributed.

## 7. Allocation of Restricted Shares of Incentive Participants

The allocation of the Restricted Shares granted among all Incentive Participants is set out in the table below:

No.	Name	Nationality	Position(s)	Class A interests (0'000 shares)	Class B interests (0'000 shares)	Number of Restricted Shares granted (0'000 shares)	Percentage to the total number of Restricted Shares granted	Percentage to the total shares of the Company as at the Grant Date
<b>I. Directors, Senior Management and Core Technical Personnel (6 persons)</b>								
1	Wang Weidong (王威東)	China	Chairman, executive Director	35	0	35	9.78%	0.0643%
2	He Ruyi (何如意)	United States	Executive Director, core technical personnel	2.42	0	2.42	0.68%	0.0044%
3	Lin Jian (林健)	China	Executive Director	1.485	0	1.485	0.41%	0.0027%
4	Fu Daotian (傅道田)	United States	President, core technical personnel	2.2	0	2.2	0.61%	0.0040%
5	Li Jia (李嘉)	China	Chief financial officer	1.485	0	1.485	0.41%	0.0027%
6	Wen Qingkai (溫慶凱)	China	Board secretary	1.815	0	1.815	0.51%	0.0033%
<b>Total</b>				<u>44.405</u>	<u>0</u>	<u>44.405</u>	<u>12.40%</u>	<u>0.0816%</u>

No.	Name	Nationality	Position(s)	Class A interests (0'000 shares)	Class B interests (0'000 shares)	Number of Restricted Shares granted (0'000 shares)	Percentage to the total number of Restricted Shares granted	Percentage to the total shares of the Company as at the Grant Date
<b>II. Other Participants</b>								
	Other de facto controllers and their spouses, parents, children, shareholders individually or jointly holding 5% or more of the Company's Shares (5 persons)			5.885	1	6.885	1.92%	0.0127%
	Foreign employees (6 persons)			10.615	0	10.615	2.97%	0.0195%
	Other employees considered by the Board to be incentivised (171 persons)			26.4	198.64	225.04	62.86%	0.4135%
<b>Total of the First Grant (188 persons)</b>				87.305	199.64	286.945	80.15%	0.5272%
<b>III. Reserved Grant</b>					71.055		19.85%	0.1306%
<b>Total</b>					358.000		100.00%	0.6578%

*Notes:*

1. The number of Shares granted to any one of the above Participants through all effective share schemes of the Company does not exceed 1% of the total shares of the Company as at the Grant Date. As at the Grant Date, the total number of Shares under the Company's effective share schemes does not exceed 20% of the total shares of the Company as at the Grant Date.
2. The aggregate number of issued Shares and Shares to be issued for the interests granted to any one of the Participant through all effective share schemes of the Company in the past 12 months does not exceed 0.1% of the relevant class of shares in issue of the Company as at the Grant Date.
3. Any difference in the total amount and the sum of the breakdowns in the above table is due to rounding.

Ten of the Incentive Participants in the First Grant are connected persons of the Company pursuant to Chapter 14A of the Listing Rules. The grant of Restricted Shares to the Connected participants under the First Grant will constitute fully exempt connected transactions of the Company and will be exempted from the reporting, announcement and independent shareholders' approval requirements under the Listing Rules. The details of the said Connected Participants and the Restricted Shares granted to them under the First Grant are set out below:

No.	Name	Reasons for being a connected person	Class A interests (0'000 shares)	Class B interests (0'000 shares)	Number of Restricted Shares granted (0'000 shares)	Percentage of the total number of Restricted Shares granted	Percentage to the total shares of the Company as at the Grant Date
1	Wang Weidong	Chairman, executive Director	35	0	35	9.78%	0.0643%
2	Lin Jian	Executive Director	1.485	0	1.485	0.41%	0.0027%
3	Wen Qingkai	Board Secretary, substantial shareholder	1.815	0	1.815	0.51%	0.0033%
4	He Ruyi	Executive Director, core technical personnel	2.42	0	2.42	0.68%	0.0044%
5	Wei Jianliang	Substantial shareholder	1.485	0	1.485	0.41%	0.0027%
6	Yang Minhua	Substantial shareholder	1.485	0	1.485	0.41%	0.0027%
7	Jiang Jing	Spouse of non-executive Director, Mr. Wang Liqiang	1.815	0	1.815	0.51%	0.0033%
8	Wang Yuxiao	Son of Mr. Wang Weidong, executive Director	1.1	0	1.1	0.31%	0.0020%
9	Wang Yinxiao	Son of Mr. Wang Xudong, substantial shareholder	0	1	1	0.28%	0.0018%
10	Yao Xuejing	Spouse of Mr. Li Zhuanglin, the Supervisor	3.3	0	3.3	0.92%	0.0061%
		<b>Total</b>	<u>49.905</u>	<u>1</u>	<u>50.905</u>	<u>14.22%</u>	<u>0.0935%</u>

*Note:* Any discrepancy arising in the decimal figures between the above total number and the direct summation of breakdown figures is due to the effect of rounded figures.



## 8. Performance Assessment Requirements

### (I) Performance assessment requirements at the Company level

According to the Assessment Management Measures, the performance assessment at the Company level of the Incentive Scheme sets different appraisal arrangements for Class A interests and Class B interests.

- ① The assessment years of the First Grant of the Class A interests shall be for the five accounting years from 2022 to 2026, and the Company's performance shall be assessed once in each accounting year. The performance assessment targets for each year are set out in the table below:

Attribution arrangements	Assessment year	Class A interests		
		Performance assessment target A	Performance assessment target B	Performance assessment target C
		100% of company Attribution	80% of company Attribution	70% of company Attribution
First Attribution Period	2022	The Company satisfies any one of the following conditions: 1. The total revenue of the Group for 2022 shall not be less than RMB750 million 2. In 2022, the Group shall launch 6 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)	The Company satisfies any one of the following conditions: 1. The total revenue of the Group for 2022 shall not be less than RMB700 million 2. In 2022, the Group shall launch 5 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)	The Company satisfies any one of the following conditions: 1. The total revenue of the Group for 2022 shall not be less than RMB650 million 2. In 2022, the Group shall launch 4 new clinical trials (including I-III phase clinical trials, achieving the first enrolment)
Second Attribution Period	2023	The Company satisfies any one of the following conditions: 1. From 2022 to 2023, the total revenue of the Group shall not be less than RMB2 billion 2. From 2022 to 2023, the Group shall launch a total of 12 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)	The Company satisfies any one of the following conditions: 1. From 2022 to 2023, the total revenue of the Group shall not be less than RMB1.8 billion 2. From 2022 to 2023, the Group shall launch a total of 10 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)	The Company satisfies any one of the following conditions: 1. From 2022 to 2023, the total revenue of the Group shall not be less than RMB1.6 billion 2. From 2022 to 2023, the Group shall launch a total of 8 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)

Attribution arrangements	Assessment year	Class A interests		
		Performance assessment target A	Performance assessment target B	Performance assessment target C
		100% of company Attribution	80% of company Attribution	70% of company Attribution
Third Attribution Period	2024	<p>The Company satisfies any one of the following conditions:</p> <ol style="list-style-type: none"> <li>From 2022 to 2024, the total revenue of the Group shall not be less than RMB4 billion</li> <li>From 2022 to 2024, the Group shall launch a total of 20 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)</li> </ol>	<p>The Company satisfies any one of the following conditions:</p> <ol style="list-style-type: none"> <li>From 2022 to 2024, the total revenue of the Group shall not be less than RMB3.6 billion</li> <li>From 2022 to 2024, the Group shall launch a total of 17 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)</li> </ol>	<p>The Company satisfies any one of the following conditions:</p> <ol style="list-style-type: none"> <li>From 2022 to 2024, the total revenue of the Group shall not be less than RMB3.3 billion</li> <li>From 2022 to 2024, the Group shall launch a total of 14 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)</li> </ol>
Fourth Attribution Period	2025	<p>The Company satisfies any one of the following conditions:</p> <ol style="list-style-type: none"> <li>From 2022 to 2025, the total revenue of the Group shall not be less than RMB7 billion</li> <li>From 2022 to 2025, the Group shall launch a total of 28 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)</li> </ol>	<p>The Company satisfies any one of the following conditions:</p> <ol style="list-style-type: none"> <li>From 2022 to 2025, the total revenue of the Group shall not be less than RMB6.5 billion</li> <li>From 2022 to 2025, the Group shall launch a total of 24 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)</li> </ol>	<p>The Company satisfies any one of the following conditions:</p> <ol style="list-style-type: none"> <li>From 2022 to 2025, the total revenue of the Group shall not be less than RMB6 billion</li> <li>From 2022 to 2025, the Group shall launch a total of 20 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)</li> </ol>
Fifth Attribution Period	2026	<p>The Company satisfies any one of the following conditions:</p> <ol style="list-style-type: none"> <li>From 2022 to 2026, the total revenue of the Group shall not be less than RMB11 billion</li> <li>From 2022 to 2026, the Group shall launch a total of 36 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)</li> </ol>	<p>The Company satisfies any one of the following conditions:</p> <ol style="list-style-type: none"> <li>From 2022 to 2026, the total revenue of the Group shall not be less than RMB10 billion</li> <li>From 2022 to 2026, the Group shall launch a total of 31 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)</li> </ol>	<p>The Company satisfies any one of the following conditions:</p> <ol style="list-style-type: none"> <li>From 2022 to 2026, the total revenue of the Group shall not be less than RMB9 billion</li> <li>From 2022 to 2026, the Group shall launch a total of 26 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)</li> </ol>

*Note:* The above “revenue” is calculated based on the data set out in the consolidated statements audited by the accounting firm engaged by the Company, excluding the overseas licencing income of telitacipt.

- ② The assessment year for the First Grant of the Class B interests shall be the four accounting years from 2023 to 2026, which shall be assessed once in each accounting year. The performance assessment targets for each year are set out in the table below:

Attribution arrangements	Assessment year	Class B interests		
		Performance assessment target A	Performance assessment target B	Performance assessment target C
		100% of company Attribution	80% of company Attribution	70% of company Attribution
First Attribution Period	2023	The Company satisfies any one of the following conditions: 1. From 2022 to 2023, the total revenue of the Group shall not be less than RMB2 billion 2. From 2022 to 2023, the Group shall a total of 12 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)	The Company satisfies any one of the following conditions: 1. From 2022 to 2023, the total revenue of the Group shall not be less than RMB1.8 billion 2. From 2022 to 2023, the Group shall launch a total of 10 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)	The Company satisfies any one of the following conditions: 1. From 2022 to 2023, the total revenue of the Group shall not be less than RMB1.6 billion 2. From 2022 to 2023, the Group shall launch a total of 8 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)
Second Attribution Period	2024	The Company satisfies any one of the following conditions: 1. From 2022 to 2024, the total revenue of the Group shall not be less than RMB4 billion 2. From 2022 to 2024, the Group shall launch a total of 20 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)	The Company satisfies any one of the following conditions: 1. From 2022 to 2024, the total revenue of the Group shall not be less than RMB3.6 billion 2. From 2022 to 2024, the Group shall launch a total of 17 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)	The Company satisfies any one of the following conditions: 1. From 2022 to 2024, the total revenue of the Group shall not be less than RMB3.3 billion 2. From 2022 to 2024, the Group shall launch a total of 14 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)

Attribution arrangements	Assessment year	Class B interests		
		Performance assessment target A	Performance assessment target B	Performance assessment target C
		100% of company Attribution	80% of company Attribution	70% of company Attribution
Third Attribution Period	2025	The Company satisfies any one of the following conditions: 1. From 2022 to 2025, the total revenue of the Group shall not be less than RMB7 billion 2. From 2022 to 2025, the Group shall launch a total of 28 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)	The Company satisfies any one of the following conditions: 1. From 2022 to 2025, the total revenue of the Group shall not be less than RMB6.5 billion 2. From 2022 to 2025, the Group shall launch a total of 24 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)	The Company satisfies any one of the following conditions: 1. From 2022 to 2025, the total revenue of the Group shall not be less than RMB6 billion 2. From 2022 to 2025, the Group shall launch a total of 20 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)
Fourth Attribution Period	2026	The Company satisfies any one of the following conditions: 1. From 2022 to 2026, the total revenue of the Group shall not be less than RMB11 billion 2. From 2022 to 2026, the Group shall launch a total of 36 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)	The Company satisfies any one of the following conditions: 1. From 2022 to 2026, the total revenue of the Group shall not be less than RMB10 billion 2. From 2022 to 2026, the Group shall launch a total of 31 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)	The Company satisfies any one of the following conditions: 1. From 2022 to 2026, the total revenue of the Group shall not be less than RMB9 billion 2. From 2022 to 2026, the Group shall launch a total of 26 new clinical trials (including I-III phase clinical trials, achieving the first patient enrolment)

*Note:* The above “revenue” is calculated based on the data set out in the consolidated financial statements audited by the accounting firm engaged by the Company, excluding the overseas licencing income of telitacicept.

(II) Performance assessment requirements at the Participant’s individual level

According to the Assessment Management Measures, the Company conducts individual performance assessment on each of the Participants during the assessment year and determines the number of Restricted Shares actually attributed to the Participants based on their assessment results. The performance assessment results of the Participants are divided into four levels, namely A, B, C and D, and the actual number of Restricted Shares to be attributed to the Participants will be determined according to the proportion of Attribution at the individual level corresponding to the following assessment rating table:

<b>Assessment results</b>	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>
Individual-level attribution ratio	<u>100%</u>			<u>0%</u>

The number of Restricted Shares actually attributed to a Participant in the Attribution period = the number of Restricted Shares planned to be attributed to the individual in that Attribution period × Company-level Attribution ratio × Individual-level Attribution ratio.

If the Restricted Shares attributed to the Participants for an Attribution period cannot be attributed or cannot be fully attributed due to assessment results, the Restricted Shares which are not attributed shall lapse and shall not be deferred to the following years.

The assessments under the Incentive Scheme are implemented in accordance with the Assessment Management Measures.

9. Clawback Mechanism

For details of the clawback mechanism in relation to handling unusual changes to the Company or the Incentive Participants under the First Grant, please refer to “Chapter XIII — Handling Unusual Changes to the Company/The Incentive Participants” of Appendix I to the circular dated December 12, 2022.

10. Shares Available For Future Grant Under the Scheme Mandate Limit

After making the First Grant, the number of shares available for future grant under the Scheme pursuant to the Scheme Mandate Limit will be 710,550 shares.

### **III. OPINION OF THE INDEPENDENT NON-EXECUTIVE DIRECTORS**

1. The Company is not subject to any circumstances where the implementation of the Scheme is prohibited under the Management Measures or other laws, regulations and normative documents. The Company is qualified to implement the Scheme.
2. The Incentive Participants of the First Grant have satisfied the employment requirements stipulated under the Company Law, the Securities Law and other laws and regulations and normative documents as well as the Articles of Association, have all met the conditions of Incentive Participants under the Scheme and have met the scope of the Incentive participants under the Scheme. The Incentive Participants under the First Grant are legally and validly qualified.
3. The First Grant is set by the Board to take place on December 28, 2022. Such Grant Date satisfied the requirements of a Grant Date as set out in the Management Measures, other laws and regulations and normative documents and the provisions of the Scheme.
4. The Company did not provide any loans, guarantee for loans or other financial support schemes or arrangements to the Incentive Participants of the First Grant.
5. The implementation of the Scheme is conducive to further improving the Company's governance structure, establishing and improving the Company's incentive and restraint mechanism, and enhancing the Company's management team and core employees' sense of responsibility and mission to achieve the Company's long-term and healthy development, which is beneficial to the Company's sustainable development, and no circumstances exist that might adversely affect the interests of the Company and all the Shareholders.

In view of the above, the independent non-executive Directors agreed that 2,869,450 Restricted Shares will be granted to 188 Incentive Participants on December 28, 2022 at a price of RMB36.36 per A Share.

### **IV. OPINION OF THE SUPERVISORY COMMITTEE**

Upon verification, the Supervisory Committee is of the view that the Incentive Participants of the First Grant have satisfied the employment requirements stipulated under the Company Law, the Securities Law, and other laws and regulations and normative documents as well as the Articles of Association, have all met the conditions of Incentive Participants under the Management Measures, the STAR Market Listing Rules and other laws and regulations and normative documents, and have all met the scope of Incentive Participants under the Scheme. The list of the Incentive Participants under the First Grant complies with the scope of the Incentive Participants as approved at the EGM and the Class Meetings.

The Supervisory Committee agreed for the First Grant to take place on December 28, 2022, and 2,869,450 Restricted Shares will be granted to 188 Incentive Participants on such date at a price of RMB36.36 per A Share.

## V. IMPACT OF THE FIRST GRANT ON THE FINANCIAL POSITION OF THE COMPANY

According to the requirements of the PRC Accounting Standards, the impact of the Restricted Shares under the First Grant of the Incentive Scheme on the accounting costs for each period is as follows:

Number of Restricted Shares under the First Grant (0'000 shares)	Total costs to be amortised (RMB0'000)	2022	2023	2024	2025	2026	2027
		(RMB0'000)	(RMB0'000)	(RMB0'000)	(RMB0'000)	(RMB0'000)	(RMB0'000)
286.945	8,264.05	240.04	2,846.59	2,411.52	1,655.92	770.81	339.17

*Notes:*

1. The above calculation results do not represent the final accounting costs. The actual accounting costs are related to the Grant Date, the Grant Price and the number of Restricted Shares attributed. If an Incentive Participant resigns before Attribution, or fails to meet the corresponding standards of the performance assessment of the Company or personal performance assessment, the actual number of shares attributed will be reduced accordingly and thus lower the share payment. Besides, the possible dilutive effects are brought to the attention of shareholders.
2. The final result of the above impact on the Company's operating results will be subject to the annual audit report issued by the accounting firm.

## VI. THE CONCLUSION OF THE LEGAL OPINION

Hai Run Law Firm issued legal opinion in relation to the First Grant, the concluding opinion of which is that the Company has obtained the required approval and authorisation in relation to the First Grant at the current stage. The Company is not subject to any circumstances where the First Grant is prohibited. The Incentive Participants under the First Grant are not subject to any circumstances where he/she is not permitted to be granted the Restricted Shares. The conditions of the First Grant are satisfied. The Grant Date, the Incentive Participants, the number of the Restricted Shares granted and the Grant Price etc. under the First Grant comply with the relevant requirements under the Incentive Scheme, the Management Measures and other laws and regulations and normative documents, and the Company is still required, among others, to fulfill its disclosure obligations according to the law and complete the relevant registration procedures for the First Grant.

## VII. THE OPINION OF THE INDEPENDENT FINANCIAL ADVISOR

Shanghai Realize Enterprise Consulting Services (Group) Co., Ltd.\* (上海榮正企業諮詢服務(集團)股份有限公司), the independent financial advisor engaged by the Company for the purposes of the Scheme, issued professional opinion in relation to the First Grant, and concluded that the Company has obtained the required approval and authorisation in relation to the Scheme, and the Company is not subject to any circumstances where the conditions for making the First Grant are not satisfied under the Scheme, and the determination of Grant Date, the Grant Price, the Incentive Participants and the number of Restricted Shares under the First Grant comply with the Management Measures, the STAR Market Listing Rules and the other laws and regulations.

By Order of the Board  
**RemeGen Co., Ltd.\***  
**Mr. Wang Weidong**  
*Chairman and executive Director*

Yantai, PRC  
December 29, 2022

*As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Dr. Ma Lan and Mr. Chen Yunjin as the independent non-executive Directors.*

\* For identification purpose only